GlassScriptPhysician profile
Glenn M Stall
NPI 1841268208
$8,616.03
in general payments reported to CMS, 2019-2025
57 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $566 · 2021: $1,398 · 2022: $1,261 · 2023: $1,477 · 2024: $1,181 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,121.83 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $1,083.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $961.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $579.36 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $411.53 | 2019-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $337.69 | 2022-2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $326.78 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $319.79 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $307.69 | 2019-2025 | |
| Esperion Therapeutics, INC. | $271.10 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.53 | 2019-2024 | Jardiance, Synjardy |
| Antares Pharma, INC. | $211.05 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Horizon Therapeutics Plc | $199.62 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $192.45 | 2019-2022 | |
| Ibsa Pharma INC. | $162.24 | 2020-2023 | Tirosint, Licart |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Stall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.